biosimilarity.blogspot.com

Biosimilarity

Friday, February 6, 2015. A new decentralized, distributed social network is emerging, and naturally people are curious. Gideon Rosenblatt asks a key question: Why Synereo instead of Facebook? I provide an answer here in six basic points that cover architecture and information flow consequences for resiliency, autonomy, and privacy, as well as important aspects of the user experience, user compensation and the attention economy. TL;DR: you are the network, not the product. Able to reveal enough about one...

http://biosimilarity.blogspot.com/

OVERVIEW OF biosimilarity.blogspot.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

7

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR BIOSIMILARITY.BLOGSPOT.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

December

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Saturday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 3.3 out of 5 with 8 reviews

5 star

1

4 star

2

3 star

4

2 star

0

1 star

1

Hey there! Start your review of biosimilarity.blogspot.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

0.6 seconds

FAVICON PREVIEW

16x16
32x32

CONTACTS AT BIOSIMILARITY.BLOGSPOT.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

7

SSL

EXTERNAL LINKS

38

SITE IP

172.217.6.65

LOAD TIME

0.57 sec

SCORE

6.2

PAGE TITLE

Biosimilarity | biosimilarity.blogspot.com Reviews

<META> DESCRIPTION

Friday, February 6, 2015. A new decentralized, distributed social network is emerging, and naturally people are curious. Gideon Rosenblatt asks a key question: Why Synereo instead of Facebook? I provide an answer here in six basic points that cover architecture and information flow consequences for resiliency, autonomy, and privacy, as well as important aspects of the user experience, user compensation and the attention economy. TL;DR: you are the network, not the product. Able to reveal enough about one...

<META> KEYWORDS

1 biosimilarity

2 why synereo

3 posted by leithaus

4 3 comments

5 reactions

6 enzymatic interaction

7 reduction

8 in the λ

9 calculus

10 as an enzyme

CONTENT

Page content here

KEYWORDS ON PAGE

biosimilarity,why synereo,posted by leithaus,3 comments,reactions,enzymatic interaction,reduction,in the λ,calculus,as an enzyme,y p x,and *x,structural equivalence,includes alpha equivalence,and makes,a commutative monoid,comm,y p comm,q comm,treating

SERVER

GSE

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Biosimilarity | biosimilarity.blogspot.com Reviews

https://biosimilarity.blogspot.com

Friday, February 6, 2015. A new decentralized, distributed social network is emerging, and naturally people are curious. Gideon Rosenblatt asks a key question: Why Synereo instead of Facebook? I provide an answer here in six basic points that cover architecture and information flow consequences for resiliency, autonomy, and privacy, as well as important aspects of the user experience, user compensation and the attention economy. TL;DR: you are the network, not the product. Able to reveal enough about one...

INTERNAL PAGES

biosimilarity.blogspot.com

1

Biosimilarity: Enzymatic interaction

http://biosimilarity.blogspot.com/2014/12/enzymatic-interaction.html

Sunday, December 21, 2014. It is traditional for me, around this time of year, to provide holiday (brain) candy for folks in my technical community. This year's offering comes from a conversation with Marius Buliga about chemlambda. In which he referred to β. This got me to thinking about explicitly modeling the COMM rule in the π-calculus as an enzyme. It turns out you can do this quite easily and it has a lot of applications! For simplicity, i'll use the reflective, higher-order π-calculus. Y )P COMM x!

2

Biosimilarity: splicious : facebook :: protunity : linkedin

http://biosimilarity.blogspot.com/2014/05/splicious-facebook-protunity-linkedin.html

Thursday, May 15, 2014. Splicious : facebook : protunity : linkedin. People don't really know what's gone into the development of www.splicious.net. A year before we launched the splicious crowd funding campaign we launched www.protunity.com. This was a test case to drive out the technology. One way to understand the relationships of these networks is via those old SAT-style analogies:. Splicious : facebook : protunity : linkedin. Really, if you look at the numbers, in terms of capital investment, and pe...

3

Biosimilarity: Why Synereo?

http://biosimilarity.blogspot.com/2015/02/why-synereo.html

Friday, February 6, 2015. A new decentralized, distributed social network is emerging, and naturally people are curious. Gideon Rosenblatt asks a key question: Why Synereo instead of Facebook? I provide an answer here in six basic points that cover architecture and information flow consequences for resiliency, autonomy, and privacy, as well as important aspects of the user experience, user compensation and the attention economy. TL;DR: you are the network, not the product. Able to reveal enough about one...

4

Biosimilarity: Imagine all the people...

http://biosimilarity.blogspot.com/2014/05/imagine-all-people.html

Wednesday, May 14, 2014. Imagine all the people. Humans are social. We have a built-in urge to share observations, insights, thoughts and feelings. We have a need to feel received. The social media with their ubiquity, easy access, and ease of use meet this need relatively well. The simple feedback mechanism, clicking a “like” or “ 1” button can be a powerful expression of sentiment and connection. Is your feed overrun with ads and TMI that you can’t organize? Imagine a world where social media served.

5

Biosimilarity: Trust the principle

http://biosimilarity.blogspot.com/2014/05/trust-principle.html

Thursday, May 29, 2014. The cryptographic e-cash community was caught off-guard by BitCoin's adoption and success. One group of researchers from PARC and Standford took heed and contemplated what factors contributed to that success. Distribution and decentralization was one of the key features they identified as contributing to BitCoin's adoption and success. From the paper:. No central point of trust. Subscribe to: Post Comments (Atom). Splicious and distributed identity. View my complete profile.

UPGRADE TO PREMIUM TO VIEW 2 MORE

TOTAL PAGES IN THIS WEBSITE

7

LINKS TO THIS WEBSITE

biosimilarity.com

BIOSIMILARITY - Clients

http://www.biosimilarity.com/clients.html

BRINGING SOFTWARE TO LIFE. WADI Environmental Science Center in Egypt. The University of Washington Behavior Research Center. The Washington State Bartenders Guild. The New Hampshire Center for Effective Behavioral Interventions and Supports.

biosimilarity.com

BIOSIMILARITY - Jobs

http://www.biosimilarity.com/jobs.html

BRINGING SOFTWARE TO LIFE. Biosimilarity LLC is looking for a the next Merlin. The initial engagement is for a limited contract. However, if things go well, who knows what adventures await?

techno-microchips.blogspot.com

Microchips: June 2009

http://techno-microchips.blogspot.com/2009_06_01_archive.html

Crochip - programmer - microchip pic - microchip programmer - pic programmer - interface - robot - controller - microcontroller. Tuesday, June 30, 2009. PIC LCD Oscilloscope for Spectrum Analyzers. This is simple and inexpensive LCD oscilloscope for spectrum analyzer display. Source code, documentation and schematic. Tags : LCD, Oscilloscope, Spectrum Analyzer, PIC, microcontroller, project src. PIC LCD Oscilloscope for Spectrum Analyzers. Source code, documentation and schematic. Monday, June 29, 2009.

kuebiko.blogspot.com

Kuebiko: June 2013

http://kuebiko.blogspot.com/2013_06_01_archive.html

More a diary than a blog. Move along nothing to see here. Wednesday, June 19, 2013. Assembly bind failure logging (Fusion) in .NET. Of how to configure it. And the steps are:. HKEY LOCAL MACHINE SOFTWARE Microsoft Fusion Add: DWORD ForceLog set value to 1 DWORD LogFailures set value to 1 DWORD LogResourceBinds set value to 1 String LogPath set value to folder for logs (e.g. C: FusionLog ). I have to restart my machine before I see results. Tuesday, June 18, 2013. Thursday, June 13, 2013. I can use TimeSp...

kuebiko.blogspot.com

Kuebiko: gitignore file repository

http://kuebiko.blogspot.com/2015/06/gitignore-file-repository.html

More a diary than a blog. Move along nothing to see here. Tuesday, June 23, 2015. Github hosts a repository. For gitignore files. C# developers are interested in VisualStudio template. To make NCrunch ignored I had to add additional line:. Subscribe to: Post Comments (Atom). Blogs I read and people I track. What is Serverless Computing? Jon Skeet: Coding Blog. Thoughts on privilege (moved! Fabulous Adventures In Coding. Shaft room, again. Damian Edwards (@DamianEdwards) Twitter.

kuebiko.blogspot.com

Kuebiko: IEnumerable Sum extension for complex type

http://kuebiko.blogspot.com/2015/06/ienumerable-sum-extension-for-complex.html

More a diary than a blog. Move along nothing to see here. Tuesday, June 23, 2015. IEnumerable Sum extension for complex type. I was not able to find a simple/working example in internet. This is how to do it:. Public static Money Sum T (this IEnumerable T data, Func T, Money selector) { var money = new Money(0); money = data.Select(selector.Invoke).Aggregate(money, (current, selectedMoney) = current selectedMoney); return money; }. Subscribe to: Post Comments (Atom). Blogs I read and people I track.

erikengbrecht.blogspot.com

Erik Engbrecht's Blog: August 2010

http://erikengbrecht.blogspot.com/2010_08_01_archive.html

Thoughts and Essays on Systems and Software Engineering. Thursday, August 26, 2010. Scala is for VB programmers. Def map[B, That](f: A = B)(implicit bf: CanBuildFrom[Repr, B, That]): That. And then someone responds like this:. Why do not people realize that Java is too difficult for the average programmer? That is the true purpose of Scala, to escape the complexity of Java code! Posted by Erik Engbrecht. Links to this post. Sunday, August 22, 2010. Scala Actors: loop, react, and schedulers. I've been wor...

kuebiko.blogspot.com

Kuebiko: Jenkins: ERROR: Failed to update

http://kuebiko.blogspot.com/2015/07/jenkins-error-failed-to-update.html

More a diary than a blog. Move along nothing to see here. Wednesday, July 15, 2015. Jenkins: ERROR: Failed to update. My dev machine was building code correctly, and everything was running. Unfortunately CI environment was throwing following exception. ITROPICS-TRUNK] $ "C: Program Files TortoiseHg/hg" - config auth.jenkins.prefix=* - config * * * * - config * * * * - config "auth.jenkins.schemes=http https" update - clean - rev default abort: C: Jenkins Workspace iTROPICS-TRUNK src/TTC&#...

UPGRADE TO PREMIUM TO VIEW 30 MORE

TOTAL LINKS TO THIS WEBSITE

38

SOCIAL ENGAGEMENT

graphsearcher

OTHER SITES

biosimilarfacts.com

Biosimilar Facts

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more. INTENDED FOR U.S. RESIDENTS ONLY. What Is a Biosimilar? Discover the Science of Biologics and Biosimilars. Watch this brief video to see how biosimilars could benefit the U.S. healthcare system. Milestone: FDA Approves First Biosimilar in the U.S. The coming revolution in much cheaper life-saving drugs. January 16, 2015. January 15, 2015. Hogan Lovells, Focus on Regulation. January 12, 2015.

biosimilargroup.biz

The Biosimilars Group

MORE ABOUT OUR OFFER. OUR NEW UNIQUE OFFER:. THE TBG ONE-DAY WORKSHOP. Get a tailor-made project plan. For your biosimilar of your choice! The Biosimilars Group is a one-stop solution provider to realize complex biosimilar projects tailored to your specific requirements. From Cell to Marketing Authorization -. Combined Excellence in Biosimilars Development. DISCOVER MORE ABOUT US. The Biosimilars Group is covering all aspects of biosimilars development from candidate identification to marketed product.

biosimilargroup.com

The Biosimilars Group

MORE ABOUT OUR OFFER. OUR NEW UNIQUE OFFER:. THE TBG ONE-DAY WORKSHOP. Get a tailor-made project plan. For your biosimilar of your choice! The Biosimilars Group is a one-stop solution provider to realize complex biosimilar projects tailored to your specific requirements. From Cell to Marketing Authorization -. Combined Excellence in Biosimilars Development. DISCOVER MORE ABOUT US. The Biosimilars Group is covering all aspects of biosimilars development from candidate identification to marketed product.

biosimilargroup.net

The Biosimilars Group

MORE ABOUT OUR OFFER. OUR NEW UNIQUE OFFER:. THE TBG ONE-DAY WORKSHOP. Get a tailor-made project plan. For your biosimilar of your choice! The Biosimilars Group is a one-stop solution provider to realize complex biosimilar projects tailored to your specific requirements. From Cell to Marketing Authorization -. Combined Excellence in Biosimilars Development. DISCOVER MORE ABOUT US. The Biosimilars Group is covering all aspects of biosimilars development from candidate identification to marketed product.

biosimilari.life

BIOSIMILARI.LIFE

Benvenuto sul portale dedicato ai farmaci biosimilari. FAQ per i Pazienti. FAQ per i Medici. FAQ per gli Acquirenti. Benvenuto sul portale dedicato ai farmaci biosimilari. FAQ per i Pazienti. FAQ per i Medici. FAQ per gli Acquirenti. Filter by Custom Post Type. Benvenuti su BIOSIMILARI.LIFE. Attivo 6 mesi, 1 settimana fa. Attivo 6 mesi, 4 settimane fa. Attivo 5 mesi, 2 settimane fa. Attivo 5 mesi, 2 settimane fa. Attivo 6 mesi, 1 settimana fa. Attivo 6 mesi, 4 settimane fa. Attivo 5 mesi, 2 settimane fa.

biosimilarity.blogspot.com

Biosimilarity

Friday, February 6, 2015. A new decentralized, distributed social network is emerging, and naturally people are curious. Gideon Rosenblatt asks a key question: Why Synereo instead of Facebook? I provide an answer here in six basic points that cover architecture and information flow consequences for resiliency, autonomy, and privacy, as well as important aspects of the user experience, user compensation and the attention economy. TL;DR: you are the network, not the product. Able to reveal enough about one...

biosimilarity.com

BIOSIMILARITY - Home

Error Page cannot be displayed. Please contact your service provider for more details. (17).

biosimilarlicensing.com

Helping the biosimilar industry do business | biosimilarlicensing.com

Become a Coxhibitor at Generic Pharma 2.0's. Attract more partnerships and. NEW PHARMA MAGAZINE NOW ONLINE! Watson Announces Preliminary 2011 Non-GAAP Earnings. IBio, Inc. Listing Deficiency Resolved. India at Biotech Crossroads. Generic Licensing is seeking Co-exhibitors for CPhI WW Spain! Darbepoetin alfa (G-CSF) 300 µg/1 mL. Filgrastim (G-CSF) 300 µg/1 mL. Pegfilgrastim (G-CSF) 6 mg/0.6 m. Rituximab 100 mg/10 mL and 500 mg/50 mL. Recombinant Human Interferon -2b. How to reach us. 44 (0)845 453 1376.

biosimilarmab.com

www.biosimilarmab.com – このドメインはお名前.comで取得されています。

biosimilarmed.com

biosimilarmed.com -&nbspThis website is for sale! -&nbspbiotechnology pharmaceutical drug biosimilar Resources and Information.

The domain biosimilarmed.com. May be for sale by its owner! This page provided to the domain owner free. By Sedo's Domain Parking. Disclaimer: Domain owner and Sedo maintain no relationship with third party advertisers. Reference to any specific service or trade mark is not controlled by Sedo or domain owner and does not constitute or imply its association, endorsement or recommendation.

biosimilarmedica.com

Biosimilar Medica

Welcome to biosimilarmedica.com. Is a great name for a biosimilar drugmaker or testing lab. As access to biosimilars. And other follow-on biologics. Expands, this domain name will be of increasing value to those adding value in this vital area of medicine. Further information on domains in this area can be found at FollowOnBiologic.com. THIS DOMAIN NAME IS FOR SALE. If you are interested in acquiring the BiosimilarMedica.com. Domain name, you can email your offer to Domains@TopChops.Net.